Pharma: Clinic Roundup

• Teva Pharmaceutical Industries Ltd., of Jerusalem, said its final Phase III study of armodafinil (Nuvigil) as adjunct therapy in adults with major depression associated with bipolar I disorder failed to achieve the primary endpoint of determining whether armodafinil (150 mg per day) is more effective than placebo as adjunct therapy to mood stabilizers and/or atypical antipsychotics.